Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Trial Profile

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms IMPROVE

Most Recent Events

  • 01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
  • 01 Jan 2018 Status changed from recruiting to completed, according to results published in the Diabetes, Obesity and Metabolism.
  • 07 Jun 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-000157-37)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top